Entries |
Document | Title | Date |
20080234315 | M3 Muscarinic Acetylcholine Receptor Antagonists - The present invention is directed to novel Muscarinic Acetylcholine receptor antagonists of Formula (I), pharmaceutical compositions and methods of using them. Compounds of Formula (I) are, inter alia, | 09-25-2008 |
20080242696 | CRYSTALLINE GRANISETRON BASE AND PRODUCTION PROCESS THEREFOR - Provided is crystalline granisetron base form I and processes for producing crystalline granisetron base form I, which is suitable for preparing, e.g., granisetron salts such as, e.g., the hydrochloride salt. Also provided is a process for producing a salt of granisetron from crystalline granisetron base form I. | 10-02-2008 |
20080249127 | Muscarinic Acetylcholine Receptor Antagonists - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 10-09-2008 |
20080275079 | M3 Muscarinic Acetylcholine Receptor Antagonists - Muscarinic Acetylcholine receptor antagonists and methods of using them are provided. | 11-06-2008 |
20080287486 | Prokinetic agent for bowel preparation - The invention provides methods of bowel preparation before a diagnostic, surgical or therapeutic procedure, in particular, bowel preparation before a colonoscopy procedure, using a 5-HT | 11-20-2008 |
20090018159 | Treatment of Diabetes - The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of diabetic patients. | 01-15-2009 |
20090030035 | 3-Aryloxy-8-aza-bicyclo[3.2.1]]oct-6-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors - This invention relates to novel 8-aza-bicyclo[3.2.1]oct-6-ene derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 01-29-2009 |
20090036483 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS - The invention provides novel quinolinone-carboxamide 5-HT | 02-05-2009 |
20090048289 | ADMINISTRATION OF TROPISETRON FOR TREATING INFLAMMATORY SKIN DISEASES/DISORDERS - Tropisetron or salt thereof, formulated into diverse pharmaceutical/dermatological compositions, is useful for the treatment of a variety of inflammatory skin disorders/diseases, e.g., eczema, psoriasis, rosacea, acne vulgaris, ulcers, seborrhoeic dermatitis and irritations induced by chemical, physical or mechanical agents, notably rosacea. | 02-19-2009 |
20090062331 | DEUTERIUM-ENRICHED MARAVIROC - The present application describes deuterium-enriched maraviroc, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
20090076071 | DEUTERIUM-ENRICHED RETAPAMULIN - The present application describes deuterium-enriched retapamulin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090137625 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors - This invention relates to novel enantiomers useful as monoamine neurotransmitter re-uptake inhibitors. | 05-28-2009 |
20090156634 | Tropane alkaloids and trigonelline combinations and methods for administering the same - A nutritional composition comprising at least an effective amount of trigonelline or derivative of trigonelline and an effective amount of tropane alkaloids, wherein the ingredients act substantially simultaneously improve the consistency of muscular contractions with respect to applied force and relaxation cycles over time and reduce the onset of central fatigue. A method of same is also provided. | 06-18-2009 |
20090170894 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - The present invention is related to a compound of formula (I) | 07-02-2009 |
20090192186 | BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES - The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. | 07-30-2009 |
20090203733 | PHARMACEUTICAL COMPOSITION - This invention relates to a pharmaceutical composition for mammals and, more particularly, to a pharmaceutical composition which enhances the action of an anaesthetic used in both human and veterinary applications, which, at least partly, reduces the risk of respiratory depression and enhances pulmonary perfusion. The pharmaceutical composition is characterised in that it contains a serotonergic ligand or any pharmacologically acceptable salt or ester thereof which acts on at least one member of the 5-HT family of serotonergic receptors, preferably on one or more of the 5-HTiA, 5-HT4 and 5-HT7 serotonergic receptors. In an example the ligand is the 8-OH-DPAT ligand. The composition can be used in conjunction with or include an anaesthetic, preferably an opioid anaesthetic, to induce a state of anaesthesia in mammals and it can be used to immobilise wile or non-domestic mammals. | 08-13-2009 |
20090270449 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS - Disclosed herein is a novel class of aminophenyl compounds having the structure: | 10-29-2009 |
20090275604 | M3 Muscarinic Acetylcholine Receptor Antagonists - Muscarinic Acetylcholine receptor antagonists and methods of using them are provided. | 11-05-2009 |
20100029711 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel chromen-2-one derivatives of Formula (I) useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 02-04-2010 |
20100048613 | POLYMORPHIC FORM OF GRANISETRON HYDROCHLORIDE AND METHODS OF MAKING THE SAME - Crystalline granisetron hydrochloride characterized by a powder x-ray diffraction pattern with peaks at about 14.3, 20.4, and 23.0±0.2 degrees two-theta and process of making the same are disclosed. | 02-25-2010 |
20100048614 | THERAPEUTIC USES OF BICYCLIC LIGANDS OF SIGMA 2 RECEPTOR - A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the σ2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors. | 02-25-2010 |
20100113508 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator - The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR. | 05-06-2010 |
20100113509 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR. | 05-06-2010 |
20100130544 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHODS AND COMPOSITIONS - The invention refers to the in vitro and in vivo use of parasympatholytic substances, preferably scopolamine, to potentiate and accelerate the differentiation of stem cells into cells with a tissue-specific phenotype, and the process and compositions related thereto. | 05-27-2010 |
20100137357 | COMPOSITIONS AND METHODS FOR HYPERHIDROSIS - The present disclosure relates, according to some embodiments, to compositions, systems, and methods for ameliorating, preventing, and/or treating (collectively “treating”) hyperhidrosis and/or excessive perspiration (collectively “hyperhidrosis”). For example, a method for treating hyperhidrosis may comprise administering (e.g., topically administering) a composition comprising an anticholinergic compound (e.g., an ipratropium compound) to a mammal. A composition (e.g., a topical composition) for treating hyperhidrosis may comprise an anticholinergic compound (e.g., an ipratropium compound) and a vehicle (e.g., a physiologically acceptable vehicle). In some embodiments, administering a composition comprising an anticholinergic compound may comprise contacting the subject with a medicated article comprising the composition. | 06-03-2010 |
20100173935 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia - Compounds of Formula IA, or pharmaceutically acceptable salts thereof: IA wherein G | 07-08-2010 |
20100190821 | 3,8-SUBSTITUTED 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel 8-aza-bicyclo[3.2.1]octane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 07-29-2010 |
20100227883 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 09-09-2010 |
20100240696 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF - The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C | 09-23-2010 |
20100261752 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS - The invention provides methods for the treatment of cognitive disorders utilizing specific 5-HT | 10-14-2010 |
20100267764 | 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors - This invention relates to novel 8-aza-bicyclo[3.2.1]octane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 10-21-2010 |
20100267765 | Pharmaceutical Compositions and Methods for CCR5 Antagonists - The present invention relates to a CCR5 antagonist compound for elevating high density lipoprotein (HDL) particles in a patient, improving plasma lipid profile in a patient or reducing triglycerides in a patient. The invention also relates to a pharmaceutical composition comprising a CCR5 antagonist compound, an HMG-CoA reductase inhibitor compound and a pharmaceutically acceptable carrier. The invention also relates to a pharmaceutical composition comprising a CCR5 antagonist compound, a cholesteryl ester transfer protein (CETP) inhibitor compound and a pharmaceutically acceptable carrier. | 10-21-2010 |
20100286193 | Novel Azabicyclo[3.2.1]Oct-2-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors - This invention relates to novel azabicyclo[3.2.1]oct-2-ene derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 11-11-2010 |
20100317690 | TREATMENT OF PROTEIN FOLDING DISORDERS - Described are various compounds and methods for the treatment of disorders arising from aberrant protein folding, including in particular lysosomal storage diseases. In particular, polyhydroxylated alkaloids and imino sugars which are pharmacoperones of an enzyme and which do not bind to a catalytic site of said enzyme are described. | 12-16-2010 |
20100324084 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - The present invention is related to a compound of formula (I) | 12-23-2010 |
20100331360 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE - [Problem] There is provided a compound useful as a preventive or remedy for cardiovascular disease, neurologic disease, metabolic disease, reproductive disease, and digestive disease. | 12-30-2010 |
20110003849 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT - Compounds of the formula: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating diabetes, inflammation, atherosclerosis, hypertension, pain and the like are disclosed. Pharmaceutical compositions and methods of use are also included. | 01-06-2011 |
20110112139 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel 8-aza-bicyclo[3.2.1]octane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 05-12-2011 |
20110118304 | METHOD FOR TREATING OVER-EATING DISORDERS - A method for treating over-eating disorders, in particular Bulimia nervosa, Binge Eating Disorder (BED), and Compulsive Over-Eating. The invention furthermore relates to novel pharmaceutical compositions for the treatment of over-eating disorders comprising a therapeutically effective amount of a compound of formula I. | 05-19-2011 |
20110118305 | COMPOUNDS - Heterocyclic amides useful as inhibitors of dipeptylpeptidase-IV (DPP-IV) enzyme, process for the preparation thereof and intermediates therefore. | 05-19-2011 |
20110124676 | BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES - The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. | 05-26-2011 |
20110144150 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE - The present invention is directed to synthetic bridged bicyclic compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. The method comprises administering to a subject a therapeutically effective amount of a Rho kinase inhibitory compound of Formula I, wherein said amount is effective to influence the actomyosin interactions, for example, by leading to cellular relaxation and alterations in cell-substratum adhesions. In one embodiment, the method treats increased intraocular pressure, such as primary open-angle glaucoma. In another embodiment, the method treats diseases or conditions of the lung associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. | 06-16-2011 |
20110144151 | NOVEL PROCESS, SALTS, COMPOSITION AND USE - The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy. | 06-16-2011 |
20110178121 | Methods for Treating Pain - The present invention is directed to methods of treating pain by administering a therapeutically effective amount of an α7 nAChR ligand or a pharmaceutically acceptable salt thereof, to a mammal in need of treatment thereof and to pharmaceutical compositions comprising such a compound or salt. | 07-21-2011 |
20110207768 | PHARMACEUTICAL COMBINATION OF ANTIBACTERIAL AND ANTIFUNGAL CREAM - A method for the emperic treatment of an intertrigal skin infection potentially caused by a gram-positive bacteria in a human patient that includes a topical administration to the patient of a pharmaceutical formulation comprising a bactericidal amount of a Gram-positive bactericide and an antimycotic amount of an antifungal component suspended in a skin-barrier carrier. | 08-25-2011 |
20110218215 | Compositions and Methods for Treating Social Anxiety - The disclosure provides a pharmaceutical composition for treating social anxiety, performance anxiety, and social phobia comprising a therapeutic amount for die treatment of a patient of a β-adrenergic receptor antagonist, an anti-diarrheal compound, and an optional anticholinergic compound. The β-adrenergic receptor antagonist may be the lipophilic β-blocker propranolol HCl, the anti-diarrheal compound may be the opioid diphenoxylate HCl, and the optional anticholinergic compound may be atropine sulfate. The composition for treating performance anxiety and social phobia can further include a pharmaceutically acceptable carrier. A method of preventing or treating social anxiety, performance anxiety, and social phobia in a patient is also provided, comprising administering a composition of the disclosure to a patient in need of such treatment. The composition administered in the present method comprises a therapeutic amount of a β-adrenergic receptor antagonist, an anti-diarrheal compound, and an optional anticholinergic compound. | 09-08-2011 |
20110257223 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator - The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to pharmaceutical compositions comprising a compound of Formula I with one or both of a Compound of Formula II and/or a Compound of Formula III. Further, the present invention relates to methods of treating CFTR mediated diseases, particularly cystic fibrosis, using modulators of CFTR, and compositions and combinations thereof. | 10-20-2011 |
20110263639 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase - Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A | 10-27-2011 |
20110263640 | 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - The present invention relates to novel 8-azabicyclo[3.2.1]oct-2-ene derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 10-27-2011 |
20110301191 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS - Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment. | 12-08-2011 |
20110312993 | AMIDO-TROPANE DERIVATIVES - The present invention relates to a compound of formula I | 12-22-2011 |
20120004257 | NOVEL COMPOUNDS - The present applications discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. In other aspects the applications discloses the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 01-05-2012 |
20120041022 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED ALKALOIDS - There is provided a process for the preparation of a single enantiomer of anhydroecgonine (of formula I): | 02-16-2012 |
20120088789 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - The present applications discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. In other aspects the applications discloses the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 04-12-2012 |
20120136024 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof - The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C | 05-31-2012 |
20120172393 | (4-Phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 07-05-2012 |
20120208841 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator - The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR. | 08-16-2012 |
20120232109 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE - [Problem] There is provided a compound useful as a preventive or remedy for cardiovascular disease, neurologic disease, metabolic disease, reproductive disease, and digestive disease. | 09-13-2012 |
20120238600 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS - The present invention discloses and claims a series of substituted tropinone benzylamines of formula (I): | 09-20-2012 |
20120264779 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS - The invention provides novel quinolinone-carboxamide 5-HT | 10-18-2012 |
20120309785 | Use of Cysteamine in Treating Parkinson's Disease - The subject invention provides materials and methods for treating neurodegenerative diseases. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat Parkinson's Disease and/or complications associated with Parkinson's Disease. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of Parkinson's Disease in an at-risk patient and/or treat or prevent the onset of Parkinson's Disease-associated symptoms. | 12-06-2012 |
20120329828 | Cocaine Analogs and Methods of Preparation and Uses Thereof - The invention provides novel cocaine analogs. The invention also provides a method of preparing cocaine analogs with control over the substituents installed at the C-1, C-2, C-3, C-4 and N-8 positions of the tropane bicyclic scaffold. The invention further provides methods of providing anesthesia, blocking reuptake of a monoamine neurotransmitter, and treating depression, by administering to a subject in need of such treatment a pharmaceutical composition comprising a compound of the invention. | 12-27-2012 |
20130040985 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - The present application discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the application discloses the use of these compounds, a method for therapy and to pharmaceutical compositions comprising these compounds. | 02-14-2013 |
20130040986 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator - The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR. | 02-14-2013 |
20130045988 | COMBINATION THERAPY - Described herein is a combination comprising at least one 5-HT | 02-21-2013 |
20130123298 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF PERIOPERATIVE ARTERIAL HYPOTENSION IN HUMANS - Pharmaceutical composition for the prevention of perioperative arterial hypotension in humans comprising noradrenaline for intravenous administration. | 05-16-2013 |
20130158071 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis. | 06-20-2013 |
20130190351 | BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES - This invention relates to bicyclic amide compounds, pharmaceutical compositions and methods for use in the prevention and treatment of a variety of conditions and/or disease states including cerebral insufficiency, through the enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors as defined herein. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in other disorders wherein a deficiency in neurotrophic factors is implicated, as well as other disorders as described herein. | 07-25-2013 |
20130197027 | HETEROCYCLYL-AZABICYCLO[3.2.1]OCTANE ANALOGS AS SELECTIVE M1 AGONISTS AND METHODS OF MAKING AND USING SAME - In one aspect, the invention relates to compounds which are useful as allosteric or bitopic agonists of the M | 08-01-2013 |
20130281485 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND USE - The present invention is directed to synthetic bridged bicyclic compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. The method comprises administering to a subject a therapeutically effective amount of a Rho kinase inhibitory compound of Formula I, wherein said amount is effective to influence the actomyosin interactions, for example, by leading to cellular relaxation and alterations in cell-substratum adhesions. In one embodiment, the method treats increased intraocular pressure, such as primary open-angle glaucoma. In another embodiment, the method treats diseases or conditions of the lung associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. | 10-24-2013 |
20130317058 | OPHTHALMIC COMPOSITION FOR ENABLING DILATION OF PUPILS - The present invention discloses an ophthalmic composition for ophthalmic application(s) inclusive of Eye examination, surgeries carried out in the posterior chamber of the Eye like cataract surgery. The said composition comprises at least three active ingredients. The said ingredients may be inclusive of, but not restricted to, Epinephrine Bitartrate, Atropine Bisulphate, Xylocaine Hydrochloride and additives like, antioxidant compounds, buffers and the like. The said composition comes in a packaging container inclusive of sterile package such as vial/ampoule/prefilled syringes. The said composition can be directly injected in the Eye in order to bring about effective and speedy dilation of the pupil(s), in particular pupil(s) of relatively smaller dimension than normal pupil. The three active ingredients are mixed in a predefined percentage range in a predefined volume and the composition is supplied in a sterile package. | 11-28-2013 |
20130324572 | REMEDY FOR PSYCHONEUROTIC DISEASES - A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient. | 12-05-2013 |
20140057939 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS - The invention provides methods for the treatment of cognitive disorders utilizing specific 5-HT | 02-27-2014 |
20140057940 | Methods for Treating or Preventing Cardiac and Neurological Disorders Using Chemokine Receptor Antagonists - The invention provides methods for treating or preventing cardiac and neurological disorders using chemokine receptor antagonists. | 02-27-2014 |
20140163062 | REMEDY FOR PSYCHONEUROTIC DISEASES - A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient. | 06-12-2014 |
20140163063 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS - The invention provides novel quinolinone-carboxamide 5-HT | 06-12-2014 |
20140206718 | Method of enhancing lysosomal alpha-Galactosidase A - A method of enhancing the activity of lysosomal α-Galactosidase A (α-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds. | 07-24-2014 |
20140235669 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - The present application discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the application discloses the use of these compounds, a method for therapy and to pharmaceutical compositions comprising these compounds. | 08-21-2014 |
20140256769 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND - The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT | 09-11-2014 |
20140288117 | USE OF CYSTEAMINE IN TREATING PARKINSON'S DISEASE - The subject invention provides materials and methods for treating neurodegenerative diseases. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat Parkinson's Disease and/or complications associated with Parkinson's Disease. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of Parkinson's Disease in an at-risk patient and/or treat or prevent the onset of Parkinson's Disease-associated symptoms. | 09-25-2014 |
20140364451 | TROPINOL ESTERS AND RELATED COMPOUNDS TO PROMOTE NORMAL PROCESSING OF APP - In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of a tropinol ester to a subject in need thereof for prophylactic or therapeutic effect. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain embodiments, methods of reducing the risk, lessening the severity, or delaying the progression or onset of a disease characterized by beta-amyloid deposits in the brain of a mammal are also provided. In certain embodiments, methods of directly or indirectly inhibiting the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (AP-P664) in a mammal are provided. | 12-11-2014 |
20150025107 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY - This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected. | 01-22-2015 |
20150073014 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND - The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms. | 03-12-2015 |
20150291580 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS - The invention provides novel quinolinone-carboxamide 5-HT | 10-15-2015 |
20150299178 | Thiazole Derivatives as Alpha 7 NACHR Modulators - Disclosed is a compound of formula (I), wherein R | 10-22-2015 |
20150306087 | PROPELLANT-FREE AEROSOL FORMULATION FOR INHALATION - The present invention relates to propellant-free aerosol formulations for inhalation containing ipratropium bromide and salbutamol. | 10-29-2015 |
20150366854 | OPHTHALMIC COMPOSITION - Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein. | 12-24-2015 |
20160009705 | OPHTHALMIC COMPOSITION | 01-14-2016 |
20160039819 | MUSCARINIC AGONISTS - Compounds of formula (I) and methods are provided for the treatment of disease or conditions in which modification of cholinergic, especially muscarinic receptor activity, has a beneficial effect. | 02-11-2016 |
20160067238 | PHARMACEUTICAL COMPOSITION AND USES THEREOF - Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia. | 03-10-2016 |
20160074344 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY - This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected. | 03-17-2016 |
20160083362 | TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME - The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 03-24-2016 |
20160095849 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND - The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT | 04-07-2016 |
20160115518 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR - The invention provides methods to identify agents useful to prevent, inhibit or treat viral infections, e.g., | 04-28-2016 |
20160376264 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS - The invention provides novel quinolinone-carboxamide 5-HT | 12-29-2016 |